在老年人中治疗慢性失眠的米尔塔扎:一个随机双盲,安慰剂控制的随机试验-MIRAGE研究
Patrick V-Q Nguyen1,2, Thien T Dang-Vu3,4, Geneviève Forest5
1Centre Hospitalier de L'Universite de Montreal - Pharmacy, 1000, St-Denis, Montreal, Québec H2X 0C1, Canada.
Age and ageing
|March 26, 2025
概括
米尔塔扎在慢性失眠的老年人中显著改善了睡眠,在28天内减少了症状严重程度. 虽然有效,但轻微的不良事件可能会限制其在这个人群中的使用.
科学领域:
- 老年医学 老年医学
- 药理学 药理学是指药理学的学科.
- 睡眠医学 睡眠医学
背景情况:
- 在老年人中,米尔塔扎平经常被处方为慢性失眠.
- 它在这个人口群体中的有效性和安全性尚未通过临床试验来确定.
- 这项MIRAGE研究旨在解决这一证据缺口.
研究的目的:
- 评估米尔塔扎在治疗65岁及以上成年人慢性失眠的疗效.
- 评估Mirtazapine在该患者群体中的安全性.
- 为提供关于米尔塔扎因治疗老年失眠的可靠临床试验数据.
主要方法:
- 进行了一项双盲,随机,安慰剂对照试验.
- 患有慢性失眠的60名参与者 (≥65岁) 每天接受米尔塔扎7.5毫克或安慰剂,持续28天.
- 主要结局是失眠严重性指数 (ISI) 评分从基线到28日的变化.
主要成果:
- 米尔塔扎平在减少失眠严重程度方面表现出优于安慰剂的优势 (平均ISI变化: -6.5对 -2.9,p=0.003).
- 通过使用米尔塔扎,在睡眠开始后的主观觉醒,总睡眠时间和睡眠效率方面观察到显著的改善.
- 没有报告严重的不良事件;然而,与安慰剂组的1人相比,在米尔塔扎组的6名参与者因轻微的不良事件而停止治疗.
结论:
- 米尔塔扎平有效地减少了老年人慢性失眠的症状.
- 药物的临床效用可能会受到轻微但相关的不良事件的发生的影响.
- 这项研究提供了第一个随机的,受控的证据支持Mirtazapine在老年失眠的使用.
相关概念视频
01:19Management of Insomnia
229
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
229
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
143
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
143
01:23Antidepressant Drugs: MAOIs and Other Agents
174
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
174
01:27Insomnia
78
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
78
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
266
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
266
01:14CNS Depressants: Barbiturates and Benzodiazepines
199
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
199